Dr. Lal PathLabs Limited (LALPATHLAB)

Name: Dr. Lal PathLabs Limited (LALPATHLAB) — histórico de demonstrações financeiras
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

Histórico de receita, lucros e fluxo de caixa das demonstrações financeiras oficiais.

Healthcare · Wall Street (EUA) · Última atualização: 2026-09-20

Dr. Lal PathLabs Limited operates laboratories for carrying out pathological investigations in India and internationally. The company provides pathological investigations of various branches of bio-chemistry, hematology, histopathology, microbiology, electrophoresis, immuno-chemistry, immunology, virology, cytology, and other pathological and radiological investigations. It also offers phlebotomist training programs. The company was founded in 1949 and is based in Gurugram, India.

Números-chave

Capitalização de mercado: ₹317 billion
Receita (exercício encerrado em 2026-03-31): ₹27.6B
Lucro líquido: ₹5.0B
Margem bruta: 80.6%
Margem líquida: 18.3%

Ver gráficos interativos e demonstrações completas →

Demonstração de resultados anual

Demonstração de resultados	2026-03-31	2025-03-31	2024-03-31	2023-03-31
Receita total	₹27.6B	₹24.6B	₹22.3B	₹20.2B
Lucro bruto	₹22.3B	₹19.8B	₹14.6B	₹12.9B
Resultado Operacional (EBIT)	₹10.2B	₹9.0B	₹4.7B	₹3.4B
Resultado líquido	₹5.0B	₹4.9B	₹3.6B	₹2.4B

Fonte: relatórios públicos da empresa (SEC). Verifique no SEC EDGAR antes de confiar em qualquer número.

Balanços, fluxos de caixa, dados trimestrais e indicadores completos no visualizador interativo de LALPATHLAB. /companies/us/LALPATHLAB

Empresas semelhantes

As informações deste site são apenas educacionais e informativas; não constituem recomendação de investimento. Não publicamos preços-alvo nem recomendações.

English version →Todas as ações

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.